FDA Inspection 1105180 — Swedish Orphan Biovitrum AB (Publ)
The FDA completed an inspection of Swedish Orphan Biovitrum AB (Publ) on Aug 29, 2019 in Stockholm. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 29, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Stockholm (Sweden)
Additional details
Postmarket Adverse Drug Experience (PADE)